The Cancer Genomics Shared Resource (CGSR) combines state-of-the-art genomic instrumentation with outstanding technical expertise. Members of the Winship Cancer Institute (Winship) benefit from services that facilitate basic science as well as translational research in a CLIA-certified environment. These services are delivered by experienced genomics professionals who ensure that all Instrumentation and procedures are rigorously quality controlled. Recent key equipment purchases underscore the CGSR's focus on new technologies and next generation sequencing for cancer research applications and include an llumina HiScan, Fluidigm Access Array, and lon Torrent Personal Genome Machine. The CSGR has been able to remain price-competitive for services through funding from the Cancer Center Support Grant (5% of annual operating costs) and Winship institutional support (30% of annual operating costs). In the past year, gene expression and methylation array data generated by the CGSR have contributed to high impact publications and successful multi-investigator grant awards including as NASA Specialized Center of Research (PI: Ya Wang, Ph.D.). With new leadership and well defined strategic initiatives, the CGSR is advancing its role in cancer diagnosis and disease classification, risk stratification, and therapeutic decision-making at the Winship Cancer Institute.
The Winship Cancer Genomics Shared Resource allows cancer scientists to conduct sophisticated genome studies that would not otherwise be feasible in their own laboratories. The data generated by the use of this facility lead to a better understanding of the genetic basis of cancer in novel service to cancer treatment and prevention.
Showing the most recent 10 out of 331 publications
